ILW Sciences Overview

  • Founded
  • 2019
Founded
  • Status
  • Private
  • Employees
  • 2
Employees
  • Latest Deal Type
  • Accelerator/​Inc
  • Investors
  • 1

ILW Sciences General Information

Description

Manufacturer of pharmaceutical alternatives intended to offer high quality and flexible vitamin contract manufacturing options. The company's alternatives includes nutraceutical, cosmetics, CBD or HEMP, packaging design, enabling brands to get the highest quality products.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
  • 100 Dale Street West Babylon
  • New York, NY 11747
  • United States
+1 (516) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

ILW Sciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Accelerator/Incubator 14-Dec-2020 Completed Generating Revenue
To view ILW Sciences’s complete valuation and funding history, request access »

ILW Sciences Executive Team (3)

Name Title Board Seat Contact Info
Chris Looney Chief Executive Officer
Isaiah White Co-Founder & Chief Operating Officer
Michael DeLuca Co-Owner
To view ILW Sciences’s complete executive team members history, request access »

ILW Sciences Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ILW Sciences Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Newchip Accelerator/Incubator 000 0000 000000 0
To view ILW Sciences’s complete investors history, request access »